Agilent: The Recovery Is Real, But So Is The Valuation (NYSE:A)
· seekingalpha.com
Agilent is rebounding in life science tools with strong recurring revenue and stabilizing margins, but DCF flags overvaluation. Read more on A stock here.
Agilent ( A ) is the kind of company I normally like: a strong position in analytical instruments, a large recurring revenue base, and exposure to long-term tre...